{"id":50138,"date":"2022-10-27T04:01:58","date_gmt":"2022-10-27T02:01:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/"},"modified":"2022-10-27T04:01:58","modified_gmt":"2022-10-27T02:01:58","slug":"milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/","title":{"rendered":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA"},"content":{"rendered":"
\n

MINNETONKA, Minn.–(BUSINESS WIRE)–Milla Pharmaceuticals Inc.<\/a><\/span>, a subsidiary of the Alter Pharma Group<\/a><\/span>, <\/i>announced it has filed its ANDA Application with Paragraph IV Certification on July 20th, 2022 and received a Paragraph IV Acknowledgement Letter and Receipt from FDA on August 31st, 2022. After providing the requisite notice to the NDA holder, the Company reports that the NDA holder has not commenced legal action against the Company within the statutory time frame. It is also worth noting the product is currently listed on FDA\u2019s Drug Shortages List<\/a><\/span>.\n<\/p>\n

<\/a><\/p>\n

\nMilla Pharmaceuticals, a subsidiary of the Alter Pharma Group, is engaged in the development, licensing, and acquisition of generic prescription drugs for the U.S. market focused on niche injectable and solution products for hospitals and clinics. This Paragraph IV Filing represents the first such filing for Milla Pharmaceuticals but the second such filing for a product of the Alter Pharma Group.\n<\/p>\n

\n\u201cAfter having received our 4th<\/sup> ANDA approval in April 2022, of which three over a period of less than one year, this second Paragraph IV Filing marks another milestone event in establishing our footprint in the U.S. market and a clear confirmation of our developmental and regulatory capabilities,<\/i>\u201d commented Milla Pharmaceuticals\u2019 President Erik Lazarich.\n<\/p>\n

\nAbout Milla Pharmaceuticals<\/a>\n<\/p>\n

\nMilla Pharmaceuticals is engaged in the development, licensing \/ acquisition, and commercialization of generic prescription drugs for the U.S. market focused on niche injectable and solution products for hospitals and clinics.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nErik Lazarich
\n
+1 (952) 449-5154
\n
erik.lazarich@millapharma.com<\/a>
About – Milla Pharmaceuticals<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MINNETONKA, Minn.–(BUSINESS WIRE)–Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced it has filed its ANDA Application with Paragraph IV Certification on July 20th, 2022 and received a Paragraph IV Acknowledgement Letter and Receipt from FDA on August 31st, 2022. After providing the requisite notice to the NDA holder, the Company reports that … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50138","6":"format-standard","7":"category-industry"},"yoast_head":"\nMilla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MINNETONKA, Minn.–(BUSINESS WIRE)–Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced it has filed its ANDA Application with Paragraph IV Certification on July 20th, 2022 and received a Paragraph IV Acknowledgement Letter and Receipt from FDA on August 31st, 2022. After providing the requisite notice to the NDA holder, the Company reports that ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T02:01:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221026006162\/en\/1615742\/21\/Logo-Milla-Pharmaceuticals-JPEG.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA\",\"datePublished\":\"2022-10-27T02:01:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/\"},\"wordCount\":268,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026006162\\\/en\\\/1615742\\\/21\\\/Logo-Milla-Pharmaceuticals-JPEG.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/\",\"name\":\"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026006162\\\/en\\\/1615742\\\/21\\\/Logo-Milla-Pharmaceuticals-JPEG.jpg\",\"datePublished\":\"2022-10-27T02:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026006162\\\/en\\\/1615742\\\/21\\\/Logo-Milla-Pharmaceuticals-JPEG.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221026006162\\\/en\\\/1615742\\\/21\\\/Logo-Milla-Pharmaceuticals-JPEG.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/","og_locale":"en_US","og_type":"article","og_title":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA - Pharma Trend","og_description":"MINNETONKA, Minn.–(BUSINESS WIRE)–Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced it has filed its ANDA Application with Paragraph IV Certification on July 20th, 2022 and received a Paragraph IV Acknowledgement Letter and Receipt from FDA on August 31st, 2022. After providing the requisite notice to the NDA holder, the Company reports that ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-27T02:01:58+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221026006162\/en\/1615742\/21\/Logo-Milla-Pharmaceuticals-JPEG.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA","datePublished":"2022-10-27T02:01:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/"},"wordCount":268,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221026006162\/en\/1615742\/21\/Logo-Milla-Pharmaceuticals-JPEG.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/","url":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/","name":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221026006162\/en\/1615742\/21\/Logo-Milla-Pharmaceuticals-JPEG.jpg","datePublished":"2022-10-27T02:01:58+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221026006162\/en\/1615742\/21\/Logo-Milla-Pharmaceuticals-JPEG.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221026006162\/en\/1615742\/21\/Logo-Milla-Pharmaceuticals-JPEG.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/milla-pharmaceuticals-inc-and-the-alter-pharma-group-announce-first-paragraph-iv-filing-and-acceptance-by-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Milla Pharmaceuticals Inc. and the Alter Pharma Group Announce First Paragraph IV Filing and Acceptance by FDA"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50138"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50138\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}